TuHURA Biosciences Concludes Merger with Kintara Therapeutics

TuHURA Biosciences, a company in phase 3 of registering immune-oncology, is creating new technologies to tackle resistance to cancer immunotherapy. They have finished the merger with Kintara Therapeutics, Inc. and are now called TuHURA Biosciences, Inc.

The new entity will be known as "TuHURA Biosciences, Inc." and will specialize in developing TuHURA's innate immune response agonists and tumor microenvironment modulators. These advanced technologies aim to address the challenges hindering the success of current cancer immunotherapies.

Due to the merger, shareholders of Kintara now collectively own around 2.85% of the combined company's common stock after the merger. Collectively, TuHURA equity holders own about 97.15% of the combined company's common stock (or about 94.55% if milestones in the CVR agreement are met) on a fully diluted basis.

“This marks a transformational milestone for both companies and is a significant step in the evolution of TuHURA. As we look to the future, which I believe has never been brighter, we are working to solve a significant issue with current cancer immunotherapies,” commented Dr. James Bianco, president and CEO of TuHURA. “Our novel technologies are designed to overcome resistance to cancer immunotherapy, and we are planning to initiate a single phase 3 accelerated approval registration trial in the first half of 2025 with our lead innate immune response agonist, IFx-2.0. If successful, not only does it provide the ability to target additional oncology indications but also unlocks tremendous value for all stakeholders.”